Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022334 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Liver Cancer
A Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00022334 is a Phase 1 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 33 participants.
The verdict
NCT00022334, a Phase 1 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have liver cancer.
Interventions
- BIOLOGICAL AFP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2001-01 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022334
The ClinicalTrials.gov registry entry for NCT00022334 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AFP is the first listed.
NCT00022334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00022334 about?
NCT00022334 is a clinical study titled "Vaccine Therapy in Treating Patients With Liver Cancer". RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have liver cancer.
What is the current status of trial NCT00022334?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2001-01. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00022334?
The interventions under investigation include: AFP (BIOLOGICAL).
Who is sponsoring clinical trial NCT00022334?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.